Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical CoTSE:4527 +2.47%83 Return-on-Tangible-Asset is 6.11% as of Mar. 2026, which is 26% below its 10-year median of 8.28. GuruFocus rates TSE:4527 with a GF Score™ of 83/100 and a GF Value™ of 円3,482.98 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,989 Consumer Packaged Goods companies, Rohto Pharmaceutical Co ranks better than 78.58% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Rohto Pharmaceutical Co's annualizedNet Income for the quarter that ended in Mar. 2026 was 円23,872 Mil. Rohto Pharmaceutical Co's average total tangible assets for the quarter that ended in Mar. 2026 was 円390,618 Mil. Therefore, Rohto Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 6.11%.
The historical rank and industry rank for Rohto Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
TSE:4527'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.98 Med: 8.28 Max: 9.71
Current: 9.11
During the past 13 years, Rohto Pharmaceutical Co's highest Return-on-Tangible-Asset was 9.71%. The lowest was 4.98%. And the median was 8.28%.
TSE:4527's Return-on-Tangible-Asset is ranked better than 78.58% of 1989
companies
in the Consumer Packaged Goods industry
Industry Median: 3.52
vs TSE:4527: 9.11
Rohto Pharmaceutical Co (TSE:4527) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Rohto Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Rohto Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Rohto Pharmaceutical Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co Return-on-Tangible-Asset Chart
TSE:4527 vs PG, CL, KVUE: Return-on-Tangible-Asset Comparison
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co Return-on-Tangible-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 6.11% mean?
Rohto Pharmaceutical Co (TSE:4527) has a Return-on-Tangible-Asset of 6.11% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Rohto Pharmaceutical Co and its competitors. This is 26% below median its historical median of 8.28. Over the past decade, Rohto Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 4.98 to 9.71. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #426 out of 1989 companies in the Consumer Packaged Goods industry, placing it in the top 21.4%.
Is Rohto Pharmaceutical Co's Return-on-Tangible-Asset too high?
Rohto Pharmaceutical Co's current Return-on-Tangible-Asset of 6.11% is 26% below median its 10-year median of 8.28. Over the past 10 years, this metric has ranged from a low of 4.98 to a high of 9.71. The Consumer Packaged Goods industry median Return-on-Tangible-Asset is 3.52. Rohto Pharmaceutical Co's value of 6.11% is 73.6% above this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #426 out of 1989 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Rohto Pharmaceutical Co has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Return-on-Tangible-Asset compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #426 out of 1989 companies for Return-on-Tangible-Asset. This places Rohto Pharmaceutical Co in the top 21% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.52. Rohto Pharmaceutical Co's value of 6.11% is 73.6% above this benchmark. Historically, Rohto Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 4.98 to 9.71 over the past decade. While the company's 10-year median is 8.28 vs. the industry median of 3.52, Rohto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Consumer Packaged Goods company?
The median Return-on-Tangible-Asset among Consumer Packaged Goods companies is 3.52, based on 1,989 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current Return-on-Tangible-Asset of 6.11% is 73.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Asset is 3.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current Return-on-Tangible-Asset is 6.11%, which is 26% below median its own 10-year median of 8.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co (TSE:4527) is currently considered Significantly Undervalued. The stock's GF Value™ is 円3,482.98, compared to a current price of 円2,362.50 — trading 32.2% below its estimated fair value. The current Return-on-Tangible-Asset is 6.11%, which is 26% below median its 10-year median of 8.28 and 73.6% above the Consumer Packaged Goods industry median of 3.52. Rohto Pharmaceutical Co's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Rohto Pharmaceutical Co (TSE:4527), the current Return-on-Tangible-Asset is 6.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (TSE:4527) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円2,362.50 is trading 32.2% below its estimated GF Value™ of 円3,482.98.
GuruFocus considers Rohto Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TSE:4527:
Return-on-Tangible-Asset: 6.11% (26% below median its 10-year median of 8.28)
GF Value™: 円3,482.98 vs. price of 円2,362.50 (32.2% below fair value)
Industry Position: 73.6% above the Consumer Packaged Goods median (#426 of 1989)
No single metric tells the full story. See the TSE:4527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
83GF Score
Get the complete analysis for TSE:4527
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4527 has been successfully added to your 
